HLA-C and neuroblastoma: These tumours are low in mutational burden15 and MHC expression16, which makes neuroblastoma both a challenging tumour to target with MHC-based immunotherapies and an ideal model for addressing the major problems currently hindering the wider advancement of cancer immunotherapies.